CFCareForward offers nutritional products at no charge to eligible patients with cystic fibrosis (CF), as well as financial and educational resources to patients and families touched by CF.
- Multivitamins in softgel, chewable, and liquid formulations.
- A variety of nutritional drinks and bars.
- Eligible CREON patients PAY $0 when commercial prescription cost is $50 or less, or as little as $5 when prescription cost is $55 or more*
- CREON CFCareForward can be used for commercial co-pay, co-insurance, and high-deductible plans*
- Referral to AbbVie Patient Assistance Foundation.
- Helpful information about exocrine pancreatic insufficiency due to CF and CREON are available online at CREON.com, as well as a variety of other educational materials such as patient emails, brochures, and pamphlets.
For more information, visit CFCareForward.com or call 1-855-CARE4WD (1-855-227-3493).
*Eligibility: Available to patients with commercial prescription insurance coverage for CREON. Co-pay assistance program and nutritional and multivitamin products are not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. This is not health insurance.
IMPORTANT SAFETY INFORMATION
- Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).
- To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
- Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
- There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
- Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
- Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
- Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
- CREON is not interchangeable with any other pancrelipase product.
CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.